Literature DB >> 6411355

Inhibition by specific monosaccharides of interleukin 2-induced thymocyte proliferation.

F Ulrich.   

Abstract

When rat thymocytes are cultured for 3 days in serum-free medium and are stimulated to divide by interleukin 2 (IL 2), concanavalin A, or sodium periodate oxidation, addition to the medium of 10-25 mM D-ribose, 2-deoxy-D-ribose, or N-acetyl-D-galactosamine inhibits by 40% or more the incorporation of [3H]thymidine. D-ribose and lectin-free IL 2 generated from sodium periodate oxidation of rat spleen cells were used to study the characteristics of this inhibition and to test possible mechanisms of inhibition. Viability of thymocytes cultured with D-ribose is similar to that of cells cultured without this sugar. In order to be inhibitory, D-ribose has to be added to the cultures within the first 24 hr, and the inhibition can be prevented if the sugar is removed 18-24 hr after the start of culture. D-Ribose does not block the absorption of IL 2 by unstimulated rat thymocytes or by concanavalin A-generated thymic or splenic blast cells. When thymocytes are cultured with D-ribose for 24 hr, inactivated with mitomycin C, and then cultured for 3 days with fresh mitogenically stimulated cells, [3H]thymidine incorporation into the latter is not altered. This suggests that the sugar does not generate suppressor cells or suppressor supernates. D-Ribose does not appear to be a general metabolic inhibitor since [3H]leucine incorporation into thymocyte proteins and the release of [3H]leucine into medium after a 2-hr. [3H]leucine pulse are not altered by D-ribose. Trivial or artifactual effects (nonspecific cytotoxicity, changes in thymidine transport, or changes in isotonicity of the culture medium) cannot explain the inhibition. A hypothetical mechanism of inhibition is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411355     DOI: 10.1016/0008-8749(83)90113-2

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  Myoadenylate deaminase deficiency: successful symptomatic therapy by high dose oral administration of ribose.

Authors:  N Zöllner; S Reiter; M Gross; D Pongratz; C D Reimers; K Gerbitz; I Paetzke; T Deufel; G Hübner
Journal:  Klin Wochenschr       Date:  1986-12-15

2.  Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiency.

Authors:  M Gross; S Reiter; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-12-04

3.  Effects of therapeutic ribose levels on human lymphocyte proliferation in vitro.

Authors:  W Pliml; T von Arnim; C Hammer
Journal:  Clin Investig       Date:  1993-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.